RYTMHealthcare · BiotechnologyThe 16 Wall Street analysts covering Rhythm Pharmaceuticals, Inc. hold a median 12-month price target of $145 — +25.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 14 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Rhythm Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (87): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Growth (47): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (18): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RYTM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +25.6% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | $145 → $146 |
| 5 Aug 2026 | Citigroup | Maintains | Buy | $142 → $143 |
| 5 Aug 2026 | Citizens | Maintains | Market Outperform | $155 → $160 |
| 5 Aug 2026 | RBC Capital | Maintains | Outperform | $141 → $155 |
| 27 July 2026 | JP Morgan | Initiates | Overweight | $145 |
| 27 July 2026 | JP Morgan | Initiates | Overweight | — |
| 7 July 2026 | RBC Capital | Maintains | Outperform | $137 → $141 |
| 7 July 2026 | RBC Capital | Maintains | Outperform | — |
| 16 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 15 June 2026 | Wells Fargo | Maintains | Overweight | — |
| 7 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 6 May 2026 | RBC Capital | Maintains | Outperform | — |
| 6 May 2026 | Wells Fargo | Maintains | Overweight | — |
| 23 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 Mar 2026 | B of A Securities | Maintains | Buy | — |
| 20 Mar 2026 | Citigroup | Maintains | Buy | — |
| 20 Mar 2026 | Citizens | Maintains | Market Outperform | — |
| 18 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Mar 2026 | HC Wainwright& Co. | Maintains | Buy | — |
| 17 Mar 2026 | B of A Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RYTM appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 97% of US stocks
Cheaper than 7% of US stocks
Cheaper than 2% of US stocks
Cheaper than 92% of US stocks
Higher than 85% of US stocks
Higher than 74% of US stocks
Higher than 95% of US stocks
Higher than 15% of US stocks
Higher than 7% of US stocks
Higher than 11% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Rhythm Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Shares of Rhythm Pharmaceuticals (RYTM) were trading higher on Wednesday, according to a Benzinga report.
Why it matters — A stock price increase on above-normal volume can signal shifting investor sentiment or market reaction to company developments.
Rhythm Pharmaceuticals announced that CEO David Meeker, M.D., and CFO Hunter Smith will participate in fireside chats at three upcoming investor conferences.
Why it matters — Investor conference participation gives RYTM management a platform to communicate the company's strategy and pipeline progress to the investment community.
Rhythm Pharmaceuticals held its Q2 2026 earnings call, with the transcript published by Seeking Alpha covering management's discussion of the quarter's results.
Why it matters — Earnings calls provide investors with management's perspective on operational performance and strategic direction for the quarter.
Rhythm Pharmaceuticals reported second-quarter 2026 global net product sales of $71.3 million for IMCIVREE, up 19% sequentially from $60.1 million in the first quarter. The company attributed the increase partly to an early positive reception of its U.S. launch in acquired hypothalamic obesity (HO).
Why it matters — A RYTM watcher would care because the sequential sales growth and early U.S. launch reception in HO signal momentum for IMCIVREE, the company's lead product.
Rhythm Pharmaceuticals reported a Q2 loss of $0.73 per share, narrower than the Zacks Consensus Estimate of a $0.81 loss and slightly better than the $0.75 per-share loss a year earlier, while also topping revenue estimates.
Why it matters — RYTM watchers would care because the company beat consensus expectations on both earnings and revenue for the quarter.
The 16 Wall Street analysts covering Rhythm Pharmaceuticals, Inc. have a median 12-month price target of $145, with estimates ranging from $105 to $160. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Rhythm Pharmaceuticals, Inc., 15 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rhythm Pharmaceuticals, Inc. 88 out of 100 across roughly 4,600 US stocks as at 14 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Aug 2026, Rhythm Pharmaceuticals, Inc. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (87 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +25.6% from the last close, and Ticker Nerd's factor model ranks Rhythm Pharmaceuticals, Inc. 88 out of 100 as at 14 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Rhythm Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RYTM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $105 to $160 over the next 12 months.
Rhythm Pharmaceuticals, Inc. returned +19.7% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Rhythm Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuroendocrine diseases, particularly those involving hyperphagia and severe obesity.
The most recent item we track (Benzinga, 12 Aug 2026): "Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?". Shares of Rhythm Pharmaceuticals (RYTM) were trading higher on Wednesday, according to a Benzinga report.
Rhythm Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuroendocrine diseases, particularly those involving hyperphagia and severe obesity. Its lead product, IMCIVREE (setmelanotide), is a precision medicine targeting rare melanocortin-4 receptor (MC4R) diseases, such as POMC deficiency and Bardet-Biedl syndrome, where traditional weight-loss treatments often prove ineffective. The company addresses unmet needs in rare disease obesity, a niche insulated from broader market dynamics in weight management drugs. Rhythm Pharmaceuticals Inc. operates in the pharmaceuticals and biotech sector, emphasizing treatments for genetic disorders that cause uncontrollable hunger and related complications. Headquartered in Boston, Massachusetts, and founded in 2008, it serves patients through specialized healthcare channels, positioning itself as a leader in rare disease therapies within the neuroendocrine space.
CEO Dr. David P. Meeker M.D. · 414 employees · United States · https://rhythmtx.com